Science News
from research organizations

Stopping transplant drugs before conception benefits fetus

Date:
October 24, 2013
Source:
American Society of Nephrology (ASN)
Summary:
Kidney transplant recipients who discontinue immunosuppressive drugs before conception have a higher rate of live births and a lower rate of birth defects without an increased risk of kidney problems.
Share:
       
FULL STORY

Research suggests that fetal exposure to mycophenolic acid products (MPA) -- which are drugs taken by transplant recipients to prevent rejection -- may increase the risk of birth defects and spontaneous abortions. Results of this study will be presented at ASN Kidney Week 2013 November 5¬-10 at the Georgia World Congress Center in Atlanta, GA.

To investigate these potential links, Serban Constantinescu, MD, PhD (Temple University School of Medicine) and his colleagues analyzed data from the National Transplantation Pregnancy Registry (NTPR), comparing 163 female kidney transplant recipients who discontinued MPA prior to conception with 114 recipients who conceived while taking MPA.

In recipients who discontinued MPA, there were more live births (79% vs. 43%), a lower incidence of miscarriages (19% vs. 52%), and a lower incidence of birth defects (6% vs. 14%). Kidney problems during and after pregnancy were similar in the two groups of transplant recipients.

"The results of this study generate multiple questions. Continued close collaboration among specialists will help to better identify potential pregnancy risks in kidney transplant recipients, particularly as new immunosuppressive agents are developed," said Dr. Constantinescu. "Individual physicians and transplant centers are encouraged to report all pregnancy exposures in transplant recipients to the National Transplantation Pregnancy Registry, which was designed specifically to assess the safety of pregnancy in solid organ transplant recipients."


Story Source:

The above post is reprinted from materials provided by American Society of Nephrology (ASN). Note: Materials may be edited for content and length.


Cite This Page:

American Society of Nephrology (ASN). "Stopping transplant drugs before conception benefits fetus." ScienceDaily. ScienceDaily, 24 October 2013. <www.sciencedaily.com/releases/2013/10/131024085832.htm>.
American Society of Nephrology (ASN). (2013, October 24). Stopping transplant drugs before conception benefits fetus. ScienceDaily. Retrieved July 5, 2015 from www.sciencedaily.com/releases/2013/10/131024085832.htm
American Society of Nephrology (ASN). "Stopping transplant drugs before conception benefits fetus." ScienceDaily. www.sciencedaily.com/releases/2013/10/131024085832.htm (accessed July 5, 2015).

Share This Page: